Follow-up assessment report on aniline: tables
Tables
Table 1: Upper-bounding Estimates of Daily Intake of Aniline by the General Population in Canada by Various Age Groups (µg/kg-bw per day)
Route of Exposure | 0 - 0.5 yrFootnote a Breast Milk FedFootnote b |
0 - 0.5 yrFootnote a Formula FedFootnote c |
0 - 0.5 yrFootnote a Fed Solid FoodFootnote d |
0.5 - 4 yrFootnote e | 5 - 11 yrFootnote f | 12 - 19 yrFootnote g | 20 - 59 yrFootnote h | 60 + yrFootnote i |
---|---|---|---|---|---|---|---|---|
Ambient AirFootnote j | <0.001 | <0.001 | <0.001 | 0.001 | 0.001 | <0.001 | <0.001 | <0.001 |
Indoor AirFootnote k | 0.013 | 0.013 | 0.013 | 0.028 | 0.022 | 0.013 | 0.011 | 0.009 |
Drinking WaterFootnote l | na | 0.053 | 0.050 | 0.023 | 0.018 | 0.010 | 0.011 | 0.011 |
Food and BeveragesFootnote m | 0.520 | nd | 0.667 | 1.11 | 0.924 | 0.384 | 0.252 | 0.200 |
SoilFootnote n | 0.001 | 0.001 | 0.001 | 0.002 | <0.001 | <0.001 | <0.001 | <0.001 |
Total Intake | 0.535 | 0.068 | 0.732 | 1.16 | 0.965 | 0.407 | 0.274 | 0.221 |
Maximum Total Intake from All Routes of Exposure - Upper-Bounding: 1.16 (µg/kg-bw per day)
Abbreviations: na = not applicable nd = no data
Table 1a: Average Estimates of Daily Intake of Aniline by the General Population in Canada by Various Age Groups (µg/kg-bw per day)
Route of Exposure | 0 - 0.5 yrFootnote a.1 Breast Milk FedFootnote b.1 |
0 - 0.5 yrFootnote a.1 Formula FedFootnote c.1 |
0 - 0.5 yrFootnote a.1 Fed Solid FoodFootnote d.1 |
0.5 - 4 yrFootnote e.1 | 5 - 11 yrFootnote f.1 | 12 - 19 yrFootnote g.1 | 20 - 59 yrFootnote h.1 | 60 + yrFootnote i.1 |
---|---|---|---|---|---|---|---|---|
Ambient AirFootnote j.1 | <0.001 | <0.001 | <0.001 | 0.001 | 0.001 | <0.001 | <0.001 | <0.001 |
Indoor AirFootnote k.1 | 0.003 | 0.003 | 0.003 | 0.006 | 0.005 | 0.003 | 0.002 | 0.002 |
Drinking WaterFootnote l.1 | na | 0.053 | 0.050 | 0.023 | 0.018 | 0.010 | 0.011 | 0.011 |
Food and BeveragesFootnote m.1 | 0.036 | nd | 0.501 | 0.690 | 0.566 | 0.241 | 0.169 | 0.139 |
SoilFootnote n.1 | 0.001 | 0.001 | 0.001 | 0.002 | <0.001 | <0.001 | <0.001 | <0.001 |
Total Intake | 0.040 | 0.058 | 0.556 | 0.722 | 0.590 | 0.254 | 0.182 | 0.152 |
Maximum Total Intake from All Routes of Exposure - Central Tendency: 0.722 (µg/kg-bw per day)
Abbreviations: na = not applicable nd = no data
Consumer Product | Scenario | Estimated intake |
---|---|---|
Marker pen AcuteFootnote a.2 exposure |
Child marking skin with ink. Exposed area is 50 cm2; ink transferred to 50 cm2 is 0.05 grams. Concentration of aniline in ink is 0.022 % (Hansen et al. 2008). Assume 100% absorption by ingestion after mouth contact with the inked skin. Aniline intake per event: 50 mg ink * 10E3 µg/mg*0.00022 g aniline per g ink /15.5 kg = 0.71 µµg/kg-bw/event |
0.71 µg/kg-bw/event |
Marker pen ChronicFootnote a.2 exposure |
Child marking skin with ink. Exposed area is a 25 cm line; ink transferred to 25 cm is 3.35 mg. Concentration of aniline in ink is 0.022 % (Hansen et al. 2008) and ink deposition rate is 134 µg/cm (ACMI 2009). Assume 100% absorption by ingestion after mouth contact with the inked skin. Aniline intake per event: 3.35 mg ink *10E3 µg/mg *0.00022 g aniline per g ink /15.5 kg = 0.047 µg/kg-bw/event Assume child uses marker pens daily. |
0.047 µg/kg-bw/day |
Polyamide cooking utensils | Preparation of soups and sauces using polyamide tools with aniline migration rate of 30 µg/litre/hour (Kantonales Laboratorium 2006). Assume that the utensil remains in the soup or sauce for one hour at 100 degrees Celsius. Using a detailed intake of foods (Health Canada, 1998), the estimated exposure to aniline arising from use of polyamide utensil from which aniline migrates to soups and sauces only, is Age: 0 - 6 mo (0.053 µg/kg-bw/day) |
0.04 to 0.14 µg/kg-bw/day |
Table 3 (Males): Tumourigenic Doses (TD05s and TDL05s) for Aniline Based on the Incidence of Splenic Tumours in Male and Female CD-F Rats (CIIT, 1982)
Tumour type | Aniline dose (mg/kg-bw per day) |
Tumour incidence | TD05 (TDL05) (mg/kg-bw per day) |
Parameter estimates |
---|---|---|---|---|
Stromal sarcoma | 0 | 0/123 | 46 (35) | Chi-square = 0.08 Degrees of freedom = 1 p-value = 0.78 |
Stromal sarcoma | 7.2 | 0/129 | 46 (35) | Chi-square = 0.08 Degrees of freedom = 1 p-value = 0.78 |
Stromal sarcoma | 21.6 | 1/128 | 46 (35) | Chi-square = 0.08 Degrees of freedom = 1 p-value = 0.78 |
Stromal sarcoma | 71.9 | 21/130 | 46 (35) | Chi-square = 0.08 Degrees of freedom = 1 p-value = 0.78 |
Hemangiosarcoma | 0 | 0/123 | 75 (61) | Chi-square = 0.17 Degrees of freedom = 2 p-value = 0.92 |
Hemangiosarcoma | 7.2 | 0/129 | 75 (61) | Chi-square = 0.17 Degrees of freedom = 2 p-value = 0.92 |
Hemangiosarcoma | 21.6 | 0/128 | 75 (61) | Chi-square = 0.17 Degrees of freedom = 2 p-value = 0.92 |
Hemangiosarcoma | 71.9 | 6/130 | 75 (61) | Chi-square = 0.17 Degrees of freedom = 2 p-value = 0.92 |
Fibrosarcoma | 0 | 0/123 | 94 (72) | Chi-square = 0.08 Degrees of freedom = 2 p-value = 0.95 |
Fibrosarcoma | 7.2 | 0/129 | 94 (72) | Chi-square = 0.08 Degrees of freedom = 2 p-value = 0.95 |
Fibrosarcoma | 21.6 | 0/128 | 94 (72) | Chi-square = 0.08 Degrees of freedom = 2 p-value = 0.95 |
Fibrosarcoma | 71.9 | 3/130 | 94 (72) | Chi-square = 0.08 Degrees of freedom = 2 p-value = 0.95 |
Osteogenic sarcoma | 0 | 0/123 | 94 (72) | Chi-square = 0.08 Degrees of freedom = 2 p-value = 0.96 |
Osteogenic sarcoma | 7.2 | 0/129 | 94 (72) | Chi-square = 0.08 Degrees of freedom = 2 p-value = 0.96 |
Osteogenic sarcoma | 21.6 | 0/128 | 94 (72) | Chi-square = 0.08 Degrees of freedom = 2 p-value = 0.96 |
Osteogenic sarcoma | 71.9 | 3/130 | 94 (72) | Chi-square = 0.08 Degrees of freedom = 2 p-value = 0.96 |
Capsular sarcoma | 0 | 0/123 | 136 (89) | Chi-square = 0.03 Degrees of freedom = 2 p-value = 0.98 |
Capsular sarcoma | 7.2 | 0/129 | 136 (89) | Chi-square = 0.03 Degrees of freedom = 2 p-value = 0.98 |
Capsular sarcoma | 21.6 | 0/128 | 136 (89) | Chi-square = 0.03 Degrees of freedom = 2 p-value = 0.98 |
Capsular sarcoma | 71.9 | 1/130 | 136 (89) | Chi-square = 0.03 Degrees of freedom = 2 p-value = 0.98 |
Table 3 (Females): Tumourigenic Doses (TD05s and TDL05s) for Aniline Based on the Incidence of Splenic Tumours in Female CD-F Rats (CIIT, 1982)
Tumour type | Aniline dose (mg/kg-bw per day) |
Tumour incidence | TD05 (TDL05) (mg/kg-bw per day) |
Parameter estimates |
---|---|---|---|---|
Hemangiosarcoma | 0 | 0/129 | 136 (89) | Chi-square = 0.03 Degrees of freedom = 2 p-value = 0.99 |
Hemangiosarcoma | 7.2 | 0/129 | 136 (89) | Chi-square = 0.03 Degrees of freedom = 2 p-value = 0.99 |
Hemangiosarcoma | 21.6 | 0/130 | 136 (89) | Chi-square = 0.03 Degrees of freedom = 2 p-value = 0.99 |
Hemangiosarcoma | 71.9 | 1/130 | 136 (89) | Chi-square = 0.03 Degrees of freedom = 2 p-value = 0.99 |
Table 4 (In vivo): Summary of Genotoxicity Data of Aniline (Based on Information Identified After June 1993)
Species, Strain, Sex etc. | Endpoint | Dose, route of exposure etc. | Results | Reference |
---|---|---|---|---|
ddY mouse and Wistar rat; male; 4/group | DNA damage (Comet Assay) | Mouse - single oral dose of aniline (100 mg/kg) |
Positive - DNA damage in the colon, liver, urinary bladder, lung, brain, and bone marrow. | Sekihashi et al., 2002. |
ddY mouse and Wistar rat; male; 4/group | DNA damage (Comet Assay) | Rat - single oral dose (150 mg/kg) | Positive - DNA damage in the stomach, colon, liver, kidney, urinary bladder and lung. | Sekihashi et al., 2002. |
Mouse ddY male | DNA damage (Comet assay) | Single oral dose of aniline (1000 mg/kg) |
Positive - DNA damage in liver, bladder, lung, brain, bone marrow Spleen was not investigated. |
Sasaki et al., 1999. |
Mouse (strain not identified in secondary source) | Chromosomal aberration assay | Intraperitoneal; 220, 300, 380 mg/kg; twice; 24 hour interval. Sampling: 16, 20 and 24 hours after second treatment. |
Negative in mouse bone marrow cells. All doses induced clinical symptoms, no cytotoxic effects were induced. |
Bayer AG, 2001b, cited in ECB, 2004. |
Mouse; CBA; male; 5/group |
Chromosomal aberration. | Intraperitoneal 220, 300, 380 mg/kg of Aniline HCl (equivalent to aniline base; two doses separated by a 24-hour interval. | Negative. | Jones and Fox, 2003. |
Mouse; B6C3F1; male; 5/group | Micronucleus induction (bone marrow) | Oral; 12, 23, 47, 120 and 470 mg/kg of aniline in corn oil; gavage; two doses; 24-hour Interval |
Weak positive response (increase in micronuclei polychromatic erythrocytes in 23 or 470 mg/kg groups, but not well correlated with dose). | Ress et al., 2002. |
Rat (strain not identified) | Micronucleus induction (bone marrow) | Single oral dose 500 mg/kg; sampling done at 48 hours. | Negative. | Bayer AG, 2001a, cited in ECB, 2004. |
Rat; PVG; male; 7/group | Micronucleus Induction (bone marrow) Study in compliance with OECD principles of GLP (revised 1997). |
Single oral dose of aniline HCl (equivalent to 0, 300, 400 and 500 mg/kg-bw of aniline base). (samples obtained 24 and 48 hours after treatment). |
Positive - dose-related induction of micronuclei observed at the 24-hour sampling time, but not following 48-hour. | Bomhard, 2003. |
Mouse; B6C3F1; male and female | Micronucleus Induction (peripheral blood) | Oral; 500, 1000 and 2000 ppm aniline HCl; 90 days. | Positive (in males and females) in polychromatic and normochromatic erythrocytes. | Witt et al., 2000. |
Table 4 (In vitro): Summary of Genotoxicity Data of Aniline (Based on Information Identified After June 1993)
Species, Strain, Sex etc. | Endpoint | Dose, route of exposure etc. | Results | Reference |
---|---|---|---|---|
Escherichia coli IC203 and IC188 |
Mutagenicity (WP2 Mutoxitest) | Aniline HCl; 1000 µg/plate | Negative | Martínez et al., 2000. |
Salmonella typhimurium (TA 98, 100) | Ames test | Aniline; 317, 325, 1250, 2500, 5000 µg/plate | Negative | Aßmann et al., 1997. |
Salmonella typhimurium (TA 98, 100) | Ames test | Aniline; 1, 10, 30, 100, 300, 1000, 3000 µg/plate | Negative (with or without S9 mix) | Chung et al., 1995; 1996. |
Sacchromyces cerevisiae (strain, RS112) | DEL recombinagenic activity) (generation of oxidative free radical species) | Aniline; 0, 5, 10, 12 mg/mL | Induction of recombination only at 12 mg/mL | Brennan and Schiestl, 1997. |
Chinese hamster ovary cells (CHO) | Chromosomal aberrations | Aniline; 444, 888, 1176, 2664 µg/mL | Positive (in the absence of hepatic activation system). | Chung et al., 1995; 1996. |
Chinese hamster lung cell line (CHL/IU) | Chromosomal aberrations | Aniline; 500, 1000, 1500, 2000, 2500 µg/mL | Positive | Matsushima et al., 1999. |
Report a problem or mistake on this page
- Date modified: